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ABSTRACT. Objective. To investigate the relationship among focal bone erosions and bone mineral density
(BMD), 25(OH) vitamin D (25OHD), and parathyroid hormone (PTH) values in patients with
rheumatoid arthritis (RA).
Methods. The study included 1191 RA patients (1014 women, 177 men, mean age 58.9 ± 11.1 yrs)
participating in a multicenter, cross-sectional study.
Results. Radiographic evidence of typical bony erosions on hands or forefeet was found in 64.1% of
patients. In those with bone erosions as compared to those without, mean BMD Z score values were
significantly lower at both the spine (–0.74 ± 1.19 vs –0.46 ± 1.31; p = 0.05) and the hip (–0.72 ±
1.07 vs –0.15 ± 1.23; p < 0.001). In the subgroup of patients not taking vitamin D supplements, PTH
levels were significantly higher in those with erosive arthritis (25.9 ± 14.0 vs 23.1 ± 11.6 pg/ml; 
p = 0.01); whereas the 25OHD concentrations were very similar in the 2 groups. The mean differ-
ences for BMD and PTH among the erosive and nonerosive RA remained statistically significant
when values were simultaneously adjusted for all disease and mineral metabolism factors (i.e., age,
sex, menopause, disease duration, Disease Activity Score 28-joint count, Health Assessment
Questionnaire, activities of daily living, Steinbrocker functional state, glucocorticoid therapy, body
weight, and bisphosphonate treatment).
Conclusion. Our results suggest that the presence of bone erosions in RA correlates with low BMD
levels and high PTH levels, and that these associations are independent of the degree of functional
impairment and other common determinants of bone mass and mineral metabolism in adults with
RA. These findings suggest that treatments to prevent bone loss or suppress PTH levels might pos-
itively affect the progression of bone erosions in RA. (First Release April 1 2011; J Rheumatol
2011;38:997–1002; doi:10.3899/jrheum.100829)
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Five years after onset of disease, 30%–50% of patients with
rheumatoid arthritis (RA) exhibit focal bone erosions1,2. A
number of clinical and biological markers have been identi-
fied as baseline risk factors for the progression of joint dam-
age in RA3,4,5,6,7. Bone erosions develop as a result of com-
plex interactions between cells and cytokines/chemokines in
the synovium and in surrounding tissues. As well as joint
destruction, RA is also associated with generalized bone
loss, with a higher prevalence of osteoporosis. Patients with
RA were reported to be at higher risk for both hip8 and ver-
tebral fractures9, but this has not been confirmed in all stud-
ies10. Both focal bone erosions and generalized osteoporosis
are related to an imbalance between osteoblast and osteo-
clast activity11,12. Inflammatory cytokines involved in the
pathophysiology of RA, such as tumor necrosis factor-α
(TNF-α) and RANKL (receptor activator of nuclear fac-
tor-κB ligand), are also associated with generalized bone
loss13,14.
Vitamin D deficiency and the associated secondary hyper-
parathyroidism are strong risk factors for osteoporosis15.
Vitamin D deficiency has been found to be associated with a
higher incidence of RA16 as well as more active disease pro-
gression17,18,19, but this was not confirmed in other stud-
ies20,21. It may therefore be that the increased risk of devel-
oping focal bone erosions in patients with RA is related with
low bone mineral density (BMD), low levels of 25(OH) vita-
min D (25OHD), and secondary hyperparathyroidism.
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The aim of our study was to investigate the relationship
between focal bone erosions and bone mass or mineral
metabolism in a large cohort of RA patients. We hypothe-
sized that lower BMD or 25OHD or higher parathyroid hor-
mone (PTH) levels would be associated with higher preva-
lence of typical RA erosions.
MATERIALS AND METHODS
The study population included 1191 consecutive patients (1014 women,
177 men) from 22 rheumatology centers uniformly distributed across Italy
(6 northern, 8 central, 8 in southern Italy). All patients fulfilled the 1987
American College of Rheumatology (ACR) revised criteria22 for RA. The
inclusion criteria were a diagnosis of established RA and an age range of
30 to 75 years, irrespective of menopausal status. Exclusion criteria were
insulin-dependent diabetes and severe hepatic or severe renal impairment
(serum creatinine > 2 mg/dl). Patients unable to walk without assistance
and those with total bilateral hip replacement were excluded, being consid-
ered unfit for a thorough clinical investigation.
All patients were interviewed and went through a full physical exami-
nation by rheumatologist at each clinical center for information on disease
and treatment history.
Disease-related findings included disease duration and counts of 28 ten-
der and swollen joints. Radiographs of hands and feet were analyzed local-
ly using the van der Heijde modification of the Sharp erosion score23, and
subjects were categorized by the presence or absence of radiographic ero-
sions (erosion score ≥ 1 vs erosion score = 0). This threshold was selected
since the total erosion score was thought to be mostly dependent on disease
duration.
Clinical measurements of RA disease activity included the Italian ver-
sion of the Health Assessment Questionnaire Disability Index (HAQ)24, the
Steinbrocker functional state25, and mobility in activities of daily life
(mobility ADL)26. The 3-variable Disease Activity Score 28-joint count
(DAS28) was calculated using C-reactive protein (CRP) and by the
Nijmegen algorithm (available online: http://www.reuma-nijmegen.nl/
www.das-score.nl/index.html).
The ACR criteria were used to classify patients as in remission or not
in remission at the time of observation. Surgical or natural menopausal age
and smoking habit were also recorded. Information was collected on
RA-specific treatments, including disease modifying antirheumatic drugs
(DMARD: methotrexate, cyclosporine, sulfasalazine, antimalarials, and
azathioprine) and TNF blockers. Patients were classified as not supple-
mented with vitamin D if they have been taking on average during the last
year < 200 IU vitamin D daily. Glucocorticoid treatment was evaluated in
detail; patients were divided into users and nonusers at the time of obser-
vation. Patients were classified as nonusers when they had never been treat-
ed with glucocorticoid or when treatment had been discontinued for more
than 6 months. Information on the current dose, treatment duration, and
cumulative doses (time per daily dose) was also obtained for each user from
the clinical notes, and when required by specifically interviewing the
patient.
Patients were interviewed on past and current use of drugs affecting
bone metabolism including bisphosphonates, calcium, and vitamin D sup-
plements. Daily intake of calcium was assessed by a simplified validated
questionnaire27. In all subjects, body weight and height (Harpender sta-
diometer) were assessed and body mass index (BMI; kg/m2) was
 calculated.
CRP, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF),
and cyclic citrullinated peptide antibody (anti-CCP) and routine biochem-
istry were measured locally.
Individual aliquots of serum samples were collected from June 2007 to
May 2008 from each patient, with a time lag of 0 to 16 months between 
X-ray or dual-energy X-ray absorptiometry (DEXA) examination. Four
aliquots were sent on dry ice by courier to the University of Verona labora-
tory and kept at –50˚C until measurements of serum intact PTH and
25OHD were taken using commercial ELISA kits (IDS Co., Bolden, UK),
with interassay coefficients of variation ranging from 5% to 15%.
Hologic (17 centers) and Lunar (2 centers) instruments were used for
DEXA evaluations of BMD at the lumbar spine and/or femoral neck in 449
patients. The values obtained with the Lunar instruments were standardized
to those of the Hologic instruments28. The in vivo coefficients of variation,
tested in each center before the start of the study, ranged from 0.6% to 1.2%
at the spine and 0.95% to 2.2% at the hip.
This study was approved by the local ethics committees, and the sub-
jects’ written consent was obtained according to the Declaration of
Helsinki.
Statistical analysis. The per-protocol main objective of the study used for
determining the sample size was the association between PTH and 25OHD
levels with disease activity and the presence of bone erosions on standard
radiographs of hands and feet.
All continuous variables are reported as mean ± standard deviations
(SD). The clinical characteristics of patients with and without erosions were
compared by chi-square test for categorical variables and Student t test for
continuous variables. Analysis of covariance was used to adjust the values
for any confounding factor: BMD or PTH or 25OHD were the dependent
variables and erosions (yes vs no) the fixed factors. All potential interfering
factors (covariates age, sex, menopausal state, disease duration, DAS28,
HAQ, mobility ADL, functional state, glucocorticoid therapy, BMI, bispho-
sphonate treatment) were included altogether in the models. All analyses
were performed with SPSS, version 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS   
Clinically relevant characteristics of the patients are listed in
Table 1. The mean age was 58.9 ± 11.1 years (range 30 and
75 yrs). Seventy-five percent of female patients had been
postmenopausal for a mean of 15 ± 8 years; 82 of these
women had undergone oophorectomy.
Seventy-nine percent of the patients were in Class I or II
Steinbrocker functional class, 19.0% were in Class III, and
1.8% were in Class IV. HAQ was < 1 in 46%, between 1 and
2 in 32%, and between 2 and 3 in 22% of patients. The
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Table 1. Characteristics of the 1191 patients (1014 women, 177 men).
Data are mean ± SD.
Characteristic Women Men
Age, yrs 58.7 ± 11.1 59.9 ± 10.8
Height, cm 160.4 ± 6.7 170.9 ± 6.3
Weight, kg 64.4 ± 12.2 75.9 ± 12.2
Body mass index, kg/m2 25.0 ± 4.5 25.9 ± 3.7
Duration of RA, mo 138 ± 104 138 ± 108
No. swollen joints 3.1 ± 5.0 2.0 ± 3.0
C-reactive protein, mg/dl 2.6 ± 5.5 2.8 ± 5.7
DAS28 3.96 ± 1.00 3.55 ± 0.97
ESR, mm3/h 30.7 ± 21.3 26.7 ± 22.4
Serum calcium, mg/dl 9.0 ± 1.1 8.9 ± 1.3
Serum phosphate, mg/dl 3.4 ± 0.7 3.2 ± 0.7
Serum 25OHD, ng/ml 24.1 ± 14.4 24.7 ± 12.4
Serum PTH, pg/ml 25.0 ± 14.1 24.9 ± 11.6
Lumbar spine BMD T score –1.70 ± 1.25 –1.40 ± 1.65
Lumbar spine BMD Z score –0.68 ± 1.18 –0.35 ± 1.65
Total hip BMD T score –1.50 ± 1.15 –1.18 ± 1.17
Total hip BMD Z score –0.58 ± 1.14 –0.23 ± 1.22
RA: rheumatoid arthritis; DAS28: Disease Activity Score 28-joint count;
ESR: erythrocyte sedimentation rate; PTH: parathyroid hormone; BMD:
bone mineral density.
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mobility ADL score was 0–6 in 35%, 6–10 in 42%, and > 10
in 35% of the patients.
Mean dietary calcium intake was 750 ± 330 mg/day.
Twenty-two percent of the patients were being treated with
calcium supplements and 45% were taking vitamin D sup-
plements. RF was positive in 63.7% of patients. Anti-CCP
measurements were available for 758 patients, and were
positive in 66.3%.
At the time of recruitment to the study, 88.2% of patients
were taking DMARD: 50.8% methotrexate, 15.9% lefluno-
mide, 10.9% antimalarials, and 3.2% either cyclosporine or
sulfasalazine. In total, 502 patients (45.5%) were being
treated with anti-TNF-α, generally in association with
methotrexate. Eighty-six percent of patients were on gluco-
corticoid treatment (mean daily dose 5.4 ± 3.5 mg pred-
nisone equivalents). Mean duration of steroid treatment was
33 ± 52 months and cumulative prednisone equivalent
intake was 11.7 ± 14.2 g.
Twenty-three percent of the patients were found to be in
clinical remission according to the ACR criteria.
The frequency of osteoporosis (i.e., T score less than
–2.5) in the overall sample was 28% for lumbar spine, 26%
for femoral neck, and 20% for total hip. At the time of
recruitment, 27.2% of the patients were being treated with
bisphosphonates.
Evidence of typical bony erosions on radiographs of
hands or forefeet was found in 64.1% of patients.
A DEXA evaluation was obtained for patients from only
10 of the 22 study centers. The patients in whom a DEXA
examination was obtained or not obtained were comparable
for all the characteristics listed in Table 1 (results not
shown).
The prevalence of the main clinical indices of disease
activity, and of the characteristics considered potentially
associated with BMD for patients with or without erosions,
are listed in Tables 2 and 3. The patients with bone erosions
generally had more severe and longer-lasting disease and
were more often taking anti-TNF-α and bisphosphonate
therapy. Both hip and spine BMD T scores and Z scores
were significantly lower in patients with bone erosions than
in those without erosions.
In the entire study population and also in the subgroup
not taking vitamin D supplements, PTH levels were signifi-
cantly higher in those with erosive arthritis, while 25OHD
concentrations were very similar in the 2 groups of patients.
Mean values for BMD, for serum 25OHD, and for PTH,
adjusted in a comprehensive model for all factors potential-
ly associated with disease activity and mineral metabolism,
are listed in Table 4. The differences between patients with
and those without erosions decreased, but remained statisti-
cally significant for hip BMD and for PTH. The individual
contribution of each covariate was very small and non-
significant, with the only exception for age as adjustment
factor for BMD values (results not shown). The exclusion of
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Table 2. Comparison between patients with and without bone erosions for continuous variables (mean ± SD).
Erosions
Characteristic Yes No p
No. 763 428
Age, yrs 59.2 ± 11.0 58.4 ± 11.4 NS
Height, cm 161.4 ± 7.4 163.0 ± 7.8 < 0.001
Weight, kg 65.2 ± 12.7 67.5 ± 13.1 0.004
Body mass index, kg/m2 25.0 ± 4.5 25.4 ± 4.4 NS
Calcium intake, mg/day 771 ± 392 805 ± 391 NS
Duration of RA, mo 155 ± 107 107 ± 92 < 0.001
No. swollen joints 3.3 ± 5.1 2.4 ± 4.0 0.003
DAS28 4.06 ± 1.00 3.61 ± 0.93 < 0.001
Daily dose (mg prednisone equivalents) 5.49 ± 3.43 5.00 ± 3.54 NS
Cumulative glucocorticoid dose†
(g prednisone equivalents) 13.5 ± 15.2 8.5 ± 11.7 < 0.001
HAQ 1.24 ± 0.86 0.96 ± 0.78 < 0.001
Mobility ADL score 8.53 ± 3.80 7.71 ± 2.77 < 0.001
Serum 25OHD, ng/ml 24.8 ± 15.4 23.9 ± 12.1 NS
21.7 ± 12.0* 20.7 ± 9.2* NS
Serum PTH, pg/ml 25.5 ± 14.4 23.7 ± 12.3 0.014
25.9 ± 14.0* 23.1 ± 11.6* 0.010
Lumbar spine BMD T score –1.75 ± 1.24 –1.50 ± 1.41 0.05
Lumbar spine BMD Z score –0.74 ± 1.19 –0.46 ± 1.31 0.05
Total hip BMD T score –1.64 ± 1.08 –1.10 ± 1.24 < 0.001
Total hip BMD Z score –0.72 ± 1.07 –0.15 ± 1.23 < 0.001
* Subgroup of patients not on treatment with vitamin D supplements. †subgroup of patients classified as users at
the time  of observation. RA: rheumatoid arthritis; DAS28: Disease Activity Score 28-joint count; HAQ: Health
Assessment Questionnaire; ADL: activities of daily living; PTH: parathyroid hormone; BMD: bone mineral den-
sity; NS: nonsignificant, p > 0.05.
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men or premenopausal women did not change the statistical
significance (results not shown) and there was no interaction
with recruitment sites. When PTH levels were adjusted also
for 25OHD levels the difference became somewhat more
significant (p value from 0.009 to 0.004).
A significant relationship was also found between values
for BMD or PTH and erosion score categorized as zero
score or quartiles of erosion score. However, this gradient of
relationship was completely lost when data were adjusted
for disease duration, which was the main determinant of ero-
sion score among patients with erosions (results not shown).
DISCUSSION
In a large cohort of RA patients with a median disease dura-
tion of 115 months we found that in patients with focal bony
erosions, total hip and lumbar spine BMD were significant-
ly lower than in patients without erosions. An additional
novel finding of our study was the association between the
presence of erosions and higher PTH levels.
At variance with the values for spine BMD, total hip
BMD values remained significantly related to erosions as
shown by values simultaneously adjusted for all available
variables potentially associated with bone mass, such as age,
disease activity (ESR, CRP, DAS28), functional impairment
(HAQ, mobility ADL), BMI, 25OHD levels, and treatment
with glucocorticoids or bisphosphonates.
The relationship between focal bone erosions and bone
metabolism has been examined in previous studies. An
ancillary finding of the COBRA trial29 was the observation
that the bone resorption markers urinary pyridinoline and
deoxypyridinoline were correlated with erosion scores. A
significant positive correlation between hand BMD and ero-
sions was reported in a number of studies, but this is to be
expected from the proximity of the erosions to the region of
BMD measurement13,30,31. A correlation between BMD at
both the hip and the spine and the Larsen score has been
observed in a cohort of 204 patients with early-onset RA32,
and from a post hoc analysis of the BeSt trial33. The pro-
gression of erosion scores was faster in patients with the
lowest BMD values34.
Recently Solomon, et al35 reported that the erosion score
was significantly correlated with total hip BMD, but not
with lumbar spine BMD. This observation, together with
our results and previous studies, might be explained by the
negative effect of functional impairment associated with
erosions and also by the effect of the severity and duration
of disease on generalized bone loss. Indeed, in Solomon’s
study the association between focal erosions and total hip
BMD lost statistical significance when BMD values were
adjusted for age, BMI, and cumulative oral glucocorticoid
dose. However, we did find that the association between
erosions and total hip BMD remained statistically signifi-
cant after adjustment for not only functional status, but also
all other potential determinants of BMD. These determi-
nants included disease duration, sex and menopausal status,
vitamin D insufficiency, and the use of glucocorticoids or
DMARD, which are known to negatively affect bone meta -
bolism. These results may be explained by sample size, as
our sample was 7 times larger than that of the previous
study35.
We found, similarly to other investigators34,35, that the
relationship with bone erosions was stronger for total hip
than for lumbar spine BMD. From the larger proportion of
trabecular bone content of the vertebral bodies relative to
total hip, one would anticipate the opposite, since the per-
turbation of cytokines occurring in RA would be expected to
have more influence on the more metabolically active tra-
becular bone tissue than on cortical bone. On the other hand,
the accuracy of lumbar spine DEXA is affected with advanc-
ing age by a number of factors36 that might dilute the rela-
tionship between BMD and erosions.
We also found an association between erosions and PTH
levels but not with serum 25OHD. Serum 25OHD was, as
expected, negatively correlated with PTH (results not
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Table 3. Association between discrete patient variables (percentages) and
bone erosions.
Bone Erosions Yes No p
Rheumatoid factor-positive 68.5 55.2 < 0.001
Anti-CCP-positive 71.2 58.1 < 0.001
Smoking 21.0 20.3 NS
Postmenopausal status 77.2 72.4 0.09
DMARD treatment 71.2 73.4 NS
Glucocorticoid treatment 86.2 85.5 NS
TNF blocker therapy 50.7 36.2 < 0.001
Vitamin D supplementation 47.6 40.2 0.014
Bisphosphonate therapy 29.3 23.4 0.026
Anti-CCP: cyclic citrullinated peptide antibody; DMARD: disease-modify-
ing antirheumatic drugs; TNF: tumor necrosis factor; NS: nonsignificant, 
p > 0.05.
Table 4. BMD, 25OHD, and parathyroid hormone (PTH) levels (mean ±
SD) after multiple adjustments (age, sex, menopausal state, disease dura-
tion, DAS28, HAQ, mobility ADL, functional state, cumulative and daily
glucocorticoid therapy, dietary calcium intake, smoking, BMI, bisphospho-
nate treatment) in RA patients with and without bone erosions. BMD val-
ues were also adjusted for 25OHD levels.
Erosions
Characteristic Yes No p
25OHD (ng/ml) 23.3 ± 12.1 24.8 ± 11.0 NS
21.8 ± 11.1* 20.2 ± 9.0*
Parathyroid hormone, pg/ml 25.7 ± 13.7 23.3 ± 13.1 0.04
26.3 ± 13.1* 22.9 ± 11.0* 0.009
Lumbar spine BMD T score –1.67 ± 1.21 –1.60 ± 1.43 NS
Lumbar spine BMD Z score –0.64 ± 1.71 –0.48 ± 0.83 NS
Total hip BMD T score –1.55 ± 1.04 –1.18 ± 1.05 0.005
Total hip BMD Z score –0.65 ± 1.02 –0.25 ± 0.99 0.005
*Patients not on treatment with vitamin D supplements. NS: nonsignificant,
p > 0.05.
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shown), but when serum PTH was adjusted for 25OHD its
association with the presence of erosions became even
stronger. These findings are difficult to interpret. RA might
be associated with decreased 1-α-hydroxylase activity,
which is able to convert 25OHD into the active vitamin D
metabolite 1.25(OH)2D, with a consequent sparing effect on
vitamin D deposits. Indeed, circulating levels of
1.25(OH)2D have been found to be negatively associated
with disease activity in RA17. It is also conceivable that in
these patients with variable vitamin D intake or sun expo-
sure (even though they were not taking vitamin D supple-
ment), PTH is a better predictor of vitamin D insufficiency,
together with calcium intake, than 25OHD itself, over a long
time interval27. Finally, it was also found that T lympho-
cytes may facilitate PTH-induced osteoclastogenesis by
increasing the bone marrow responsiveness of stromal cells
to PTH37.
This observational study has a number of limitations.
With its cross-sectional design we associate measurements
(BMD or PTH levels) taken at a given timepoint with ero-
sions that are dependent on the disease duration and on ther-
apy. BMD values were adjusted for all available factors, but
other potential confounders (e.g., family history, dietary
habits in childhood, etc.) could not be taken into account.
The hand and foot radiographs were analyzed using the van
der Heijde modification of the Sharp erosion score23 in each
center, without centralized supervision. We also established,
per protocol, a definition of typical erosions by a score ≥ 1,
which is less likely to be associated with large inter-site
variability. The study included patients receiving bisphos-
phonates, but this factor could not be excluded since bis-
phosphonate treatment is likely to reflect previous diagnosis
of osteoporosis. Hand and foot radiographs were not taken
simultaneously with DEXA evaluation. The time lag
between DEXA scanning or serum collection and radiogra-
phy ranged from 0 to 16 months, but this interval was short-
er (< 4 months) in patients with early RA (< 3 years), and >
6 months only in patients with stable longterm disease.
Our results suggest that the presence of bone erosions in
RA correlates with low BMD levels, and that this associa-
tion is independent of both functional impairment and other
common determinants of bone mass in adult subjects. It
appears that bone erosions and generalized osteoporosis
share a common pathophysiological mechanism and that
osteoporosis might be an independent risk factor for the
development of bone erosions. This might imply that anti -
resorption agents should be considered for the management
of RA at onset of disease. PTH levels are also associated
with the presence of bone erosions by a mechanism that is
not associated with vitamin D deficiency. Interventional
studies of the effect of treatments aimed at preventing bone
loss or suppressing PTH levels on the appearance and pro-
gression of bone erosions in RA could shed light on the clin-
ical relevance of these associations.
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